Clinical Course and Side Effects of Anti-IgE Monoclonal Antibody in Patients with Severe Persistent Asthma

Yalçın A. D., Bişgin A., ÇETİNKAYA R., Yıldırım M., Gorczynski R. M.

CLINICAL LABORATORY, vol.59, no.1-2, pp.71-77, 2013 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 59 Issue: 1-2
  • Publication Date: 2013
  • Doi Number: 10.7754/clin.lab.2012.120406
  • Journal Name: CLINICAL LABORATORY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.71-77
  • Keywords: omalizumab, side effects, severe persistent asthma, anti IgE, MPV, platelet, clinical course, MEAN PLATELET VOLUME, SEVERE ALLERGIC-ASTHMA, OMALIZUMAB TREATMENT, RHINITIS, DISEASE, ATHEROSCLEROSIS, ACTIVATION, EFFICACY
  • Akdeniz University Affiliated: No

Abstract

Background: Omalizumab, a recombinant humanized monoclonal antibody to IgE, is recommended as a new option for the treatment of severe persistent allergic asthma. The purpose of this study is to assess the effects omalizumab treatment on life quality and its side effects in severe persistent asthma patients.